Company intelligence / Profile preview

Vocan Brazil Biotechnologies

Brazil

Ownership: Private
Development stage: Other

Overview

Vocan Brazil Biotechnologies is a fully funded pharmaceutical company in Brazil that plans to run clinical trials with biosynthetic psilocybin produced using Vocan Biotechnologies/Core One Labs’ proprietary low‑cost fermentation-based platform, once manufacturing is ready and regulatory pathways allow.[3][7] As of the latest available information, no clinical trials have yet been initiated or reported.[3][7]

Therapeutic areas: Psychiatry
Modalities: Small molecule
Industry: Biotech

Partnerships

Core One Labs (technology owner/licensor)Vocan Biotechnologies (technology developer/licensor)

Beyond the preview

Go deeper on Vocan Brazil Biotechnologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vocan Brazil Biotechnologies.

Explore the full profile